NOVO.B.DK

305.95

-1.62%↓

HLUNB.DK

40.26

+0.35%↑

AMBUB.DK

80.15

-1.23%↓

NOVO.B.DK

305.95

-1.62%↓

HLUNB.DK

40.26

+0.35%↑

AMBUB.DK

80.15

-1.23%↓

NOVO.B.DK

305.95

-1.62%↓

HLUNB.DK

40.26

+0.35%↑

AMBUB.DK

80.15

-1.23%↓

NOVO.B.DK

305.95

-1.62%↓

HLUNB.DK

40.26

+0.35%↑

AMBUB.DK

80.15

-1.23%↓

NOVO.B.DK

305.95

-1.62%↓

HLUNB.DK

40.26

+0.35%↑

AMBUB.DK

80.15

-1.23%↓

Search

Coloplast A-S (Class B)

Fermé

479 -1.64

Résumé

Variation du prix de l'action

24h

Actuel

Min

478.5

Max

489.5

Chiffres clés

By Trading Economics

Revenu

522M

1.4B

Ventes

83M

7B

P/E

Moyenne du Secteur

27.421

110.024

BPA

6.32

Rendement du dividende

4.84

Marge bénéficiaire

19.835

Employés

16,983

EBITDA

309M

2.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.84%

2.26%

Prochains Résultats

12 mai 2026

Date du Prochain Détachement de Dividende

18 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-9.1B

110B

Ouverture précédente

480.64

Clôture précédente

479

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 févr. 2026, 22:31 UTC

Résultats

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 févr. 2026, 22:18 UTC

Résultats

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 févr. 2026, 22:11 UTC

Résultats

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 févr. 2026, 21:52 UTC

Résultats

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 févr. 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 févr. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 févr. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 févr. 2026, 23:34 UTC

Market Talk
Résultats

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 févr. 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 févr. 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 févr. 2026, 22:45 UTC

Résultats

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 févr. 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 févr. 2026, 22:37 UTC

Résultats

Nutrien 4Q EPS $1.18 >NTR.T

18 févr. 2026, 22:37 UTC

Résultats

Nutrien 4Q Sales $5.34B >NTR.T

18 févr. 2026, 22:35 UTC

Résultats

Pan American Silver 4Q EPS $1.07 >PAAS

18 févr. 2026, 22:35 UTC

Résultats

Pan American Silver 4Q Rev $1.18B >PAAS

18 févr. 2026, 22:30 UTC

Résultats

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 févr. 2026, 22:29 UTC

Résultats

Kinross Gold 4Q EPS 75c >K.T

18 févr. 2026, 22:22 UTC

Résultats

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 févr. 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 févr. 2026, 22:16 UTC

Résultats

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 févr. 2026, 22:05 UTC

Résultats

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 févr. 2026, 22:03 UTC

Résultats

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 févr. 2026, 22:02 UTC

Résultats

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 févr. 2026, 22:02 UTC

Résultats

Kaiser Aluminum 4Q Sales $929M >KALU

18 févr. 2026, 22:02 UTC

Résultats

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 févr. 2026, 22:00 UTC

Résultats

Kinross Gold 4Q Adj EPS 67c >KGC

18 févr. 2026, 22:00 UTC

Résultats

Kinross Gold 4Q Sales $2.02B >KGC

18 févr. 2026, 21:56 UTC

Résultats

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 févr. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Comparaison

Variation de prix

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat